Efficacy and safety of the use of the antiparasitic drug Vepripak ® in comparison with Bravecto® for the prevention and treatment of ectoparasitosis and vector-borne diseases (babesiosis) in dogs

Ectoparasitoses are widespread in nature and have a negative impact on their health and quality of life in dogs, exacerbate chronic diseases and reduce immunity. In addition, their pathogens are carriers of many natural diseases. For the complex and most effective treatment and prevention of ectoparasitosis, the use of systemic drugs is most preferable, it is to this type of drugs that the new medicinal product for veterinary use Vepripak ® from Vetstem LLC belongs. The main active ingredient of Vepripak ® is a fluorolaner, which has high insecto-acaricidal activity and is characterized by a long protective period. The aim of this study is to compare the therapeutic efficacy, safety and digestibility of the drug Vepriak®, with similar characteristics of the reference drug Bravecto®.